Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P43897
UPID:
EFTS_HUMAN
Alternative names:
-
Alternative UPACC:
P43897; B4E391; F5H2T7; Q561V7; Q8TBC2; Q9UQK0
Background:
Elongation factor Ts, mitochondrial (EF-Ts, mitochondrial), encoded by the gene with accession number P43897, plays a pivotal role in protein synthesis. It facilitates the exchange of GDP to GTP, remaining bound to the aminoacyl-tRNA.EF-Tu.GTP complex during the GTP hydrolysis stage on the ribosome. This process is crucial for the efficient translation of genetic information into functional proteins.
Therapeutic significance:
The protein is implicated in Combined oxidative phosphorylation deficiency 3, a mitochondrial disease characterized by severe metabolic acidosis and encephalomyopathy or hypertrophic cardiomyopathy. This association highlights the protein's potential as a target for therapeutic intervention in mitochondrial disorders.